Targeting LIN28: a new hope in prostate cancer theranostics

Garima Shrivastava; Alaa Aa Aljabali; Seyed Hossein Shahcheraghi; Marzieh Lotfi; Madhur D Shastri; Shakti D Shukla; Dinesh K Chellappan; Niraj Kumar Jha; Krishnan Anand; Harish Dureja; Ritesh M Pabari; Vijay Mishra; Abdulmajeed G Almutary; Abdullah M Alnuqaydan; Nitin Charbe; Parteek Prasher; Poonam Negi; Rohit Goyal; Kamal Dua; Gaurav Gupta; Ángel Serrano-aroca; Bojlul Bahar; Debmalya Barh; Pritam Kumar Panda; Kazuo Takayama; Kenneth Lundstorm; Paul Mccarron; Hamid Bakshi; Murtaza M Tambuwala

doi:10.2217/fon-2021-0247

Targeting LIN28: a new hope in prostate cancer theranostics

Garima Shrivastava, Alaa Aa Aljabali, Seyed Hossein Shahcheraghi, Marzieh Lotfi, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj Kumar Jha, Krishnan Anand, Harish Dureja, Ritesh M Pabari, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Poonam Negi, Rohit Goyal, Kamal Dua, Gaurav GuptaÁngel Serrano-aroca, Bojlul Bahar, Debmalya Barh, Pritam Kumar Panda, Kazuo Takayama, Kenneth Lundstorm, Paul Mccarron, Hamid Bakshi, Murtaza M Tambuwala

Research output: Contribution to journal › Special issue › peer-review

10 Citations (Scopus)

36 Downloads (Pure)

Abstract

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

Original language	English
Pages (from-to)	3873-3880
Number of pages	8
Journal	Future Oncology
Volume	17
Issue number	29
Early online date	15 Jul 2021
DOIs	https://doi.org/10.2217/fon-2021-0247
Publication status	Published (in print/issue) - 31 Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.

Keywords

Cancer
theranostic
Therapeutic
LIN28B
prostate cancer
LIN28A
Special Report
biomarker
Humans
Male
Molecular Targeted Therapy
RNA-Binding Proteins/metabolism
Prostatic Neoplasms/pathology
Precision Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2021-0247

fon-2021-0247Final published version, 3.12 MBLicence: CC BY

Cite this

Shrivastava, G., Aljabali, A. A., Shahcheraghi, S. H., Lotfi, M., Shastri, M. D., Shukla, S. D., Chellappan, D. K., Jha, N. K., Anand, K., Dureja, H., Pabari, R. M., Mishra, V., Almutary, A. G., Alnuqaydan, A. M., Charbe, N., Prasher, P., Negi, P., Goyal, R., Dua, K., ... Tambuwala, M. M. (2021). Targeting LIN28: a new hope in prostate cancer theranostics. Future Oncology, 17(29), 3873-3880. https://doi.org/10.2217/fon-2021-0247

@article{3e8ee56231a040faa8665e5bc0b08e6a,

title = "Targeting LIN28: a new hope in prostate cancer theranostics",

abstract = "The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.",

keywords = "Cancer, theranostic, Therapeutic, LIN28B, prostate cancer, LIN28A, Special Report, biomarker, Humans, Male, Molecular Targeted Therapy, RNA-Binding Proteins/metabolism, Prostatic Neoplasms/pathology, Precision Medicine",

author = "Garima Shrivastava and Aljabali, {Alaa Aa} and Shahcheraghi, {Seyed Hossein} and Marzieh Lotfi and Shastri, {Madhur D} and Shukla, {Shakti D} and Chellappan, {Dinesh K} and Jha, {Niraj Kumar} and Krishnan Anand and Harish Dureja and Pabari, {Ritesh M} and Vijay Mishra and Almutary, {Abdulmajeed G} and Alnuqaydan, {Abdullah M} and Nitin Charbe and Parteek Prasher and Poonam Negi and Rohit Goyal and Kamal Dua and Gaurav Gupta and {\'A}ngel Serrano-aroca and Bojlul Bahar and Debmalya Barh and Panda, {Pritam Kumar} and Kazuo Takayama and Kenneth Lundstorm and Paul Mccarron and Hamid Bakshi and Tambuwala, {Murtaza M}",

year = "2021",

month = oct,

day = "31",

doi = "10.2217/fon-2021-0247",

language = "English",

volume = "17",

pages = "3873--3880",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "29",

}

Shrivastava, G, Aljabali, AA, Shahcheraghi, SH, Lotfi, M, Shastri, MD, Shukla, SD, Chellappan, DK, Jha, NK, Anand, K, Dureja, H, Pabari, RM, Mishra, V, Almutary, AG, Alnuqaydan, AM, Charbe, N, Prasher, P, Negi, P, Goyal, R, Dua, K, Gupta, G, Serrano-aroca, Á, Bahar, B, Barh, D, Panda, PK, Takayama, K, Lundstorm, K, Mccarron, P, Bakshi, H & Tambuwala, MM 2021, 'Targeting LIN28: a new hope in prostate cancer theranostics', Future Oncology, vol. 17, no. 29, pp. 3873-3880. https://doi.org/10.2217/fon-2021-0247

TY - JOUR

T1 - Targeting LIN28: a new hope in prostate cancer theranostics

AU - Shrivastava, Garima

AU - Aljabali, Alaa Aa

AU - Shahcheraghi, Seyed Hossein

AU - Lotfi, Marzieh

AU - Shastri, Madhur D

AU - Shukla, Shakti D

AU - Chellappan, Dinesh K

AU - Jha, Niraj Kumar

AU - Anand, Krishnan

AU - Dureja, Harish

AU - Pabari, Ritesh M

AU - Mishra, Vijay

AU - Almutary, Abdulmajeed G

AU - Alnuqaydan, Abdullah M

AU - Charbe, Nitin

AU - Prasher, Parteek

AU - Negi, Poonam

AU - Goyal, Rohit

AU - Dua, Kamal

AU - Gupta, Gaurav

AU - Serrano-aroca, Ángel

AU - Bahar, Bojlul

AU - Barh, Debmalya

AU - Panda, Pritam Kumar

AU - Takayama, Kazuo

AU - Lundstorm, Kenneth

AU - Mccarron, Paul

AU - Bakshi, Hamid

AU - Tambuwala, Murtaza M

PY - 2021/10/31

Y1 - 2021/10/31

N2 - The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

AB - The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

KW - Cancer

KW - theranostic

KW - Therapeutic

KW - LIN28B

KW - prostate cancer

KW - LIN28A

KW - Special Report

KW - biomarker

KW - Humans

KW - Male

KW - Molecular Targeted Therapy

KW - RNA-Binding Proteins/metabolism

KW - Prostatic Neoplasms/pathology

KW - Precision Medicine

UR - https://pubmed.ncbi.nlm.nih.gov/34263659/

UR - http://www.scopus.com/inward/record.url?scp=85116468129&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0247

DO - 10.2217/fon-2021-0247

M3 - Special issue

C2 - 34263659

SN - 1479-6694

VL - 17

SP - 3873

EP - 3880

JO - Future Oncology

JF - Future Oncology

IS - 29

ER -

Targeting LIN28: a new hope in prostate cancer theranostics

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this